| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2568 | 2010 |
| Prognostic significance of autoimmunity during treatment of melanoma with interferon H Gogas, J Ioannovich, U Dafni, C Stavropoulou-Giokas, K Frangia, ... New England Journal of Medicine 354 (7), 709-718, 2006 | 762 | 2006 |
| Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis P Blanchard, A Lee, S Marguet, J Leclercq, WT Ng, J Ma, ATC Chan, ... The lancet oncology 16 (6), 645-655, 2015 | 740 | 2015 |
| Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer FJ Couch, SN Hart, P Sharma, AE Toland, X Wang, P Miron, JE Olson, ... Journal of clinical oncology 33 (4), 304, 2015 | 726 | 2015 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 646 | 2013 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 641 | 2017 |
| A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general … AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ... Nature genetics 42 (10), 885-892, 2010 | 406 | 2010 |
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 395 | 2017 |
| NCCN guidelines insights: pancreatic adenocarcinoma, version 1.2019: featured updates to the NCCN guidelines MA Tempero, MP Malafa, EG Chiorean, B Czito, C Scaife, AK Narang, ... Journal of the National Comprehensive Cancer Network 17 (3), 202-210, 2019 | 373 | 2019 |
| A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer CA Haiman, GK Chen, CM Vachon, F Canzian, A Dunning, RC Millikan, ... Nature genetics 43 (12), 1210-1214, 2011 | 348 | 2011 |
| Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non–small-cell lung cancer: a phase III randomized trial P Kosmidis, N Mylonakis, C Nicolaides, C Kalophonos, E Samantas, ... Journal of clinical oncology 20 (17), 3578-3585, 2002 | 338 | 2002 |
| Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials IJ Dahabreh, H Linardou, F Siannis, G Fountzilas, S Murray The oncologist 13 (6), 620-630, 2008 | 330 | 2008 |
| What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis L Ribassin-Majed, S Marguet, AWM Lee, WT Ng, J Ma, ATC Chan, ... Journal of Clinical Oncology 35 (5), 498-505, 2017 | 325 | 2017 |
| Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: A Hellenic Co-operative Oncology Group study DV Skarlos, E Samantas, P Kosmidis, G Fountzilas, M Angelidou, ... Annals of Oncology 5 (7), 601-607, 1994 | 325 | 1994 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 314 | 2019 |
| Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a … G Fountzilas, E Ciuleanu, M Bobos, A Kalogera-Fountzila, AG Eleftheraki, ... Annals of oncology 23 (2), 427-435, 2012 | 291 | 2012 |
| Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial M Karthaus, A Kretzschmar, H Kröning, M Biakhov, D Irwin, N Marschner, ... Annals of Oncology 17 (2), 289-296, 2006 | 271 | 2006 |
| Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study CJA Punt, A Nagy, JY Douillard, A Figer, T Skovsgaard, J Monson, ... The Lancet 360 (9334), 671-677, 2002 | 270 | 2002 |
| A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic … GP Stathopoulos, K Syrigos, G Aravantinos, A Polyzos, P Papakotoulas, ... British journal of cancer 95 (5), 587-592, 2006 | 262 | 2006 |
| Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study E Briasoulis, H Kalofonos, D Bafaloukos, E Samantas, G Fountzilas, ... | 254 | 2000 |
